Organon (OGN) reported $1.59 billion in revenue for the quarter ended June 2025, representing a year-over-year decline of 0.8%. EPS of $1.00 for the same period compares to $1.12 a year ago.
The reported revenue represents a surprise of +2.63% over the Zacks Consensus Estimate of $1.55 billion. With the consensus EPS estimate being $0.94, the EPS surprise was +6.38%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Organon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Established Brands- U.S.- Respiratory- Singulair: $2 million compared to the $1.95 million average estimate based on three analysts. The reported number represents a change of 0% year over year.
- Revenue- Women's Health- Int'l- Nexplanon/Implanon NXT: $77 million versus $75.7 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10% change.
- Revenue- Women's Health- U.S.- NuvaRing: $7 million versus $7 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -30% change.
- Revenue- Women's Health- Int'l- Follistim AQ: $43 million versus $41.53 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +7.5% change.
- Revenue- Women's Health- Nexplanon/Implanon NXT: $240 million versus $258.98 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -0.8% change.
- Revenue- Women's Health- Follistim AQ: $74 million versus $69.57 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +19.4% change.
- Revenue- Established Brands Total: $936 million versus $905.64 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -2.8% change.
- Revenue- Biosimilars Total: $173 million versus the three-analyst average estimate of $153.98 million. The reported number represents a year-over-year change of +5.5%.
- Revenue- Women?s Health Total: $462 million versus the three-analyst average estimate of $471.79 million. The reported number represents a year-over-year change of +2.9%.
- Revenue- Other Total: $23 million versus $21.74 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -25.8% change.
- Revenue- Women's Health- NuvaRing: $28 million versus $22.99 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -3.5% change.
- Revenue- Biosimilars- Renflexis: $63 million versus the three-analyst average estimate of $56.8 million. The reported number represents a year-over-year change of -8.7%.
View all Key Company Metrics for Organon here>>>
Shares of Organon have returned -0.5% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Organon & Co. (OGN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
